SK Biopharmaceuticals found joint venture with Glycyx
SK Biopharmaceuticals(CEO Jung-Woo Cho) announced the company founded a joint venture to develop Relenopride as a rare nervous disease treatment with Glycyx Therapeutics Ltd. On the 7th. SK Biopharmaceuticals and Glycyx will start its clinical development from the year of 2018 after founding the ...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.